Reducing blood pressure is fundamental to reducing cardiovascular risk.
Adalat® GITS reduces cardiovascular risk by combining effective blood pressure reduction with excellent vascular protective activity. There is broad evidence for this dual effect from the INSIGHT1 and ENCORE data.2
The ACTION trial was designed to determine how these effects translate into long-term clinical benefits. The ACTION trial results were released at the ESC Congress 2004 in August in Munich, Germany, and have since been published in The Lancet.3 For further information, please have a look at our ACTION website.
1. Brown MJ, et al. Lancet 2000;356:366–72.
2. ENCORE Investigators. Circulation 2003;107(3):422-8.
3. Poole-Wilson P, et al. Lancet 2004;364:849–57.
